Physician profile
Amir M Torabi
NPI 1548223324
$16,735.24
in general payments reported to CMS, 2019-2025
55 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 84% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,699 · 2020: $1,850 · 2021: $1,577 · 2022: $2,198 · 2023: $2,842 · 2024: $2,418 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,172 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,172.15 |
| Education | $238.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,500.96 | 2019-2025 | Nuplazid, Daybue |
| Ucb, INC. | $1,375.54 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Emd Serono, INC. | $1,323.99 | 2019-2025 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $1,128.01 | 2019-2023 | Oxtellar Xr |
| Biogen, INC. | $1,026.17 | 2019-2025 | Tysabri, Vumerity |
| Abbvie INC. | $892.33 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $783.44 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $658.33 | 2019-2025 | |
| Sk Life Science, INC. | $598.35 | 2020-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $590.54 | 2019-2022 | |
| Pfizer INC. | $582.86 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $564.10 | 2019-2024 | Rytary |
| Impel Pharmaceuticals INC. | $419.77 | 2023 | Trudhesa |
| Eisai INC. | $419.32 | 2020-2025 | |
| Impel Pharmaceuticals LLC | $417.32 | 2024-2025 | Trudhesa |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Torabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.